External Catheter Market: as CDC 2024 data confirming 14.7% US adult diabetes prevalence and FDA documentation of 722,000 annual US healthcare-associated infections establish the chronic disease and CAUTI prevention demand base sustaining external catheter adoption across acute and long-term care settings, Medline exclusive US acute care distribution of Consure Medical QiVi MEC from April 2024 and Wellspect Surity Female External Catheter launched in January 2026 confirm that competitive intensity is intensifying across both male condom catheter and female external catheter sub-categories, so BD continence care expansion in March 2026 and Hollister silicone catheter launches in February 2026 validate the market's continued double-digit growth trajectory through the 2026 to 2035 forecast period.

The global external catheter market size was USD 2.92 Billion in 2025 and is expected to register a revenue CAGR of 6.1% during the forecast period. Market revenue growth is driven by factors such as the 14.7% US adult diabetes prevalence confirmed by CDC 2024 data creating a structurally large neurogenic and diabetic bladder dysfunction patient population requiring long-term external catheter management, the FDA documentation of 722,000 annual US healthcare-associated infections sustaining hospital CAUTI prevention investment in catheter-free external urinary collection alternatives, and as well as the expanding competitive landscape with Medline/Consure QiVi MEC, Wellspect Surity, and BD continence care expansion all validating the commercial scale of the external catheter category. The first driving factor is the CDC 2024 confirmation of 14.7% US adult diabetes prevalence, representing approximately 38 million Americans with diabetes whose neurogenic bladder complications and associated urinary incontinence create a large and growing long-term external catheter patient population at home care, long-term care, and specialist urology outpatient settings. The second driving factor is the FDA documentation of 722,000 annual US healthcare-associated infections, with catheter-associated urinary tract infections representing the single largest HAI category, sustaining institutional investment in external urinary collection alternatives to indwelling catheterisation that eliminate the primary CAUTI transmission pathway at hospital medical-surgical, ICU, and long-term care nursing unit settings. The third driving factor is the expanding competitive validation of the external catheter category through multiple product launches and distribution agreements including Medline exclusive US acute care distribution of Consure Medical QiVi MEC in April 2024, Wellspect HealthCare Surity Female External Catheter launch in January 2026, BD continence care programme expansion in March 2026, and Hollister silicone condom catheters in February 2026, all confirming that leading continence care companies view the external catheter category as a high-priority commercial growth platform. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way demographic aging compounds both the diabetic bladder dysfunction and the post-stroke urinary incontinence patient populations that represent the primary long-term external catheter market, which allows the structural aging of the developed-market population to generate recurring external catheter demand growth independently of healthcare spending cycle variation. Once a patient with diabetic neurogenic bladder or post-stroke urinary incontinence is established on an external catheter management protocol, the per-patient daily disposable catheter demand continues indefinitely through the home care and long-term care settings that manage these patients on a chronic rather than episodic basis, generating a durable recurring revenue stream per established patient that compounds as each year's new diabetic bladder dysfunction and post-stroke incontinence patient cohort adds to the existing external catheter patient population base. As a result, demand and revenue share are concentrating around the external catheter platforms with the broadest product range across male and female patient populations, the deepest distribution channels into both hospital supply chains and home care reimbursement systems, and the most comprehensive continence nursing service support programmes, and the forecast tilts toward these integrated continence care platform providers rather than single-product external catheter competitors without equivalent distribution breadth. For instance, in August 2024, Avalon GloboCare received 510(k) clearance for the GeeWhiz External Catheter for male patients, one of several commercial and regulatory events that expanded the competitive landscape in the 12 months to Q2 2026. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the structural size and growth of the diabetic bladder dysfunction patient population that drives long-term recurring external catheter demand in home care and long-term care settings, because diabetic peripheral neuropathy and autonomic dysfunction affecting bladder innervation creates a chronic urinary incontinence condition requiring daily external catheter management that persists indefinitely as long as the underlying diabetes is managed rather than resolved. Chronic disease demand works commercially because each newly diagnosed adult with diabetic neuropathic bladder dysfunction requires assessment and fitting for an appropriate external catheter format, and once established on a home care external catheter management protocol generates daily disposable catheter demand for the duration of their chronic condition, creating a compounding patient population base that grows with each year's new diabetic bladder dysfunction incidence above the existing patient stock. CDC 2024 data confirmed 14.7% US adult diabetes prevalence, representing approximately 38 million Americans with diabetes of whom a significant proportion develop urinary complications including bladder dysfunction and urinary incontinence requiring external catheter management. The FDA documentation of 722,000 annual US healthcare-associated infections provides the institutional demand anchor that sustains hospital CAUTI prevention protocol investment in external catheter alternatives to indwelling catheterisation. In August 2024, Avalon GloboCare received FDA 510(k) clearance for the GeeWhiz External Catheter for male patients, validating the commercial opportunity in the external catheter category and expanding the male external catheter product portfolio available to hospital and home care procurement. These are some of the key factors driving revenue growth of the market.

The second driver is the institutional CAUTI prevention investment sustained by FDA HAI documentation and CMS financial penalties for above-benchmark CAUTI rates, because the financial accountability created by CMS value-based purchasing programmes elevates CAUTI prevention from a nursing quality initiative to a hospital CFO-level financial risk management priority, protecting external catheter procurement from discretionary supply cost-containment in the same way that patient safety compliance spending is protected from operational cost reduction. CAUTI prevention protocol demand works commercially because once a hospital nursing unit's CAUTI prevention protocol specifies external urinary collection for patients meeting specified clinical criteria across both male condom catheter and female external catheter formats, the per-nursing-unit external catheter daily disposable demand becomes predictable from census volume rather than variable with individual nursing staff clinical judgement, sustaining reliable per-account disposable revenue growth. In April 2024, Medline became the exclusive US acute care distributor of Consure Medical's QiVi MEC female external catheter, validating institutional interest in external catheter category expansion beyond BD PureWick at the hospital supply chain level. In May 2024, the National Association for Continence's We Count initiative reported continued growth in external catheter user populations across both male and female patient groups at US hospital and home care settings. The effect on the market is that FDA 722,000 annual US HAI documentation creates a persistent institutional liability awareness that sustains CAUTI prevention programme investment above the level that discretionary quality improvement spending alone would generate, protecting external catheter protocol adoption from hospital cost-containment pressure. These are some of the key factors driving revenue growth of the market.

CDC 2024 confirmed 14.7% US adult diabetes prevalence, approximately 38 million Americans with diabetes. FDA documented 722,000 annual US healthcare-associated infections. Together these two primary-source figures establish the dual demand drivers sustaining external catheter market growth: the chronic disease population requiring long-term home care urinary management and the institutional CAUTI liability awareness that drives hospital protocol adoption of catheter-free external collection alternatives. Neither demand driver is discretionary, both compound with demographic aging.

The third driver is the competitive category validation created by multiple leading continence care companies committing to external catheter product launches and distribution expansion within a 24-month window, because competitive investment by Wellspect, BD, Hollister, and Avalon GloboCare simultaneously confirms that the external catheter category has achieved the commercial scale that justifies product development investment by companies with established continence care customer relationships and distribution infrastructure. Competitive category investment works commercially because each new product launch by a category entrant with established hospital or home care distribution relationships adds new hospital accounts to the external catheter procurement ecosystem that had not previously adopted external catheterisation protocols, expanding the total addressable market above the existing BD PureWick and Hollister male catheter installed customer base. Wellspect HealthCare launched the Surity Female External Catheter in January 2026, entering the female external catheter market with its established continence nursing specialist relationships at European and North American hospital urology and continence care departments. BD expanded its continence care programme in March 2026 to include distribution support and clinical education resources for external catheter protocol adoption at hospital accounts where BD PureWick had existing supply chain positioning. Hollister launched updated silicone condom catheters in February 2026 targeting the male external catheter home care market with extended-wear silicone formulations designed for improved skin tolerance during long-duration use. These are some of the key factors driving revenue growth of the market.

However, the external catheter market faces adoption constraints from home care reimbursement variability and product performance limitations at diverse patient anatomical profiles. Because Medicare Part B and state Medicaid coverage determinations for external catheters require specific clinical documentation of functional incontinence meeting payer-defined medical necessity criteria that varies across Medicare contractor jurisdictions and state Medicaid programme policies, the administrative burden of establishing home care external catheter reimbursement creates a prescribing friction that limits the commercially accessible home care patient population to those whose clinicians have navigated the reimbursement documentation pathway, creating a coverage gap between the epidemiologically available external catheter patient population and the commercially reimbursed patient population. Product performance limitations are a second constraint, as both male condom catheters and female external wick-based catheters experience leakage failure rates in the range of 15 to 25% in real-world home use studies at first-time users, requiring repeat nursing specialist fitting assessments and product size and format adjustments that add clinical support cost and reduce new-user adoption success rates compared to the clinical performance benchmarks established in hospital nursing unit adoption settings with trained continence nursing specialist oversight. The clinical prescribing awareness gap is the third constraint, as the absence of systematic external catheter product knowledge in medical school and residency curricula means that the prescribing pathway for home care external catheters depends primarily on continence nurse specialist referral and patient self-advocacy rather than physician-initiated external catheter prescribing, limiting the conversion rate from the epidemiologically identified patient population to the commercially managed patient population. These factors substantially limit external catheter market growth over the forecast period.

Based on product, the global external catheter market is segmented into male condom external catheters, female external catheters, penile sheath extended-wear systems, and accessories and leg bags. Male condom external catheters hold the largest revenue share at approximately 54%, anchored by Hollister male external catheter leadership across hospital, long-term care, and home care settings in North America and Europe, and Coloplast Conveen male condom catheter strong European hospital and home care positioning. Female external catheters are expected to register the most rapid revenue growth rate in the global external catheter market over the forecast period, driven by BD PureWick double-digit growth, Wellspect Surity launch January 2026, QiVi MEC Medline distribution, and TillaCath 2.0 FDA clearance April 2026 collectively expanding the female external catheter product ecosystem and hospital protocol adoption base.

Based on end-use, the global external catheter market is segmented into hospitals and acute care units, long-term care and nursing facilities, and home care and community. Hospitals and acute care units hold the largest revenue share, driven by CAUTI prevention protocol adoption of external catheters for both male and female patients and BD PureWick hospital supply chain positioning. Home care is expected to register the most rapid revenue growth rate in the global external catheter market over the forecast period, driven by CDC 14.7% US adult diabetes prevalence creating a large home care bladder management patient population and aging-in-place trends expanding the home care external catheter user base above the long-term care facility resident population.

Based on regional analysis, the external catheter market in North America accounted for largest revenue share in 2025 at approximately 40% of global revenue. The United States drives the regional position through CDC 14.7% adult diabetes prevalence, FDA 722,000 annual US HAI documentation sustaining CAUTI prevention investment, BD PureWick female external catheter supply chain dominance, and Hollister male external catheter distribution depth across hospital, long-term care, and home care channels. The Iran-US sanctions and Strait of Hormuz disruption do not materially affect external catheter primary and secondary supply chains, given that silicone and thermoplastic elastomer catheter component manufacturing is concentrated in North American and European production facilities outside the affected logistics corridors.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, the United Kingdom, and the Netherlands represent the four largest national external catheter markets in Europe. Coloplast and Hollister both have strong European male condom catheter commercial positions through hospital and home care supply channels. Wellspect HealthCare's Surity Female External Catheter January 2026 launch positions the company for European market entry through its established continence care specialist nursing relationships at European hospital urology and continence departments.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan, China, Australia, and South Korea represent the four largest national external catheter markets in the region. Japan's aging population and high hospital nursing standards create a favourable adoption environment for male and female external catheters at hospital geriatric care and long-term care settings. China's expanding hospital infection prevention quality improvement initiatives create awareness of CAUTI prevention protocols that include external catheterisation alternatives to indwelling catheters at tier 1 and tier 2 city hospital networks.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national external catheter markets. Brazil's private hospital and home care networks in major urban centres are the primary external catheter adoption settings, constrained by public sector procurement budget limitations at SUS-funded hospital settings where indwelling catheterisation remains the predominant urinary management modality.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and UAE represent the primary commercial markets. GCC private hospital networks and long-term care facilities serving geriatric and diabetic patient populations are adopting CAUTI prevention protocols that include external catheterisation alternatives at Joint Commission International accredited facilities, supported by institutional infection prevention programme investment under JCI standard requirements.